EDISON EQUITY RESEARCH - AMARANTUS BIOSCIENCE

Edison Investment Research: Amarantus BioScience - Potential of LymPro indicated

Amarantus presented data of its blood-based diagnostic test for Alzheimer’s disease (AD), LymPro, at the Alzheimer’s Association International Conference (AAIC). Data from a 41-patient trial with an optimised test showed a specificity of 81% and a sensitivity of 73%. Commercial launch of LymPro as a laboratory-developed test remains on track for H214. MANF has also started formal preclinical testing and could begin clinical development in 2015. Eltoprazine is expected to start a Phase IIb trial in the coming months.

Amarantus BioScience is a US-based biotechnology company developing diagnostic and therapeutic products. Its lead product is LymPro, a blood-based diagnostic test for Alzheimer’s disease. It also has two therapeutic products in development, eltoprazine in Phase II and MANF in preclinical studies.

 To view our full report, please click here: 

http://www.edisoninvestmentresearch.com/research/report/amarantus-bioscience1

 Click 

here

 to view all of Edison Investment Research's published reports.